Currently there is no description available for Jennifer Martin.
“The reason it’s such a prolonged approval process in Australia and New Zealand is because there is lots of double checking and reexamining of the statistics, because if we make an error, it will become an error on a big scale by the time the drug is rolled out across a large population. It’s not that uncommon that the regulator might look at the data and say, 'Well, it looks OK in terms of how it works in European people, but we’re quite worried about how this might affect Indigenous people, and the Asian population seem to respond differently too'. Australia and New Zealand are saying; 'Why would you put people at risk when if you wait a bit longer, you can get more information?'”
08 Jan 2021
4
3
Read More
